Stockscreener 앱 받기
7.35
6.83%
0.47
전일 마감가:
$6.88
열려 있는:
$6.94
하루 거래량:
253.45K
Relative Volume:
0.34
시가총액:
$65.36M
수익:
-
순이익/손실:
$-7.82M
주가수익비율:
-6.4108
EPS:
-1.1465
순현금흐름:
$-8.00M
1주 성능:
+30.09%
1개월 성능:
-18.33%
6개월 성능:
+398.54%
1년 성능:
+261.18%
1일 변동 폭
$6.56
$7.60
1주일 범위
$5.55
$7.60
52주 변동 폭
$0.72
$20.32
에데사 바이오테크 Stock (EDSA) Company Profile
명칭
Edesa Biotech Inc
전화
(905) 475-1234
주소
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
7.35 | 65.36M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
에데사 바이오테크 주식(EDSA)의 최신 뉴스
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares - simplywall.st
Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group - Stock Titan
Edesa Biotech Inc (EDSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edesa Biotech announces $3.5M PIPE financing - MSN
Edesa Biotech Inc (EDSA) Institutional Confidence - TradingKey
Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edesa Biotech Inc (EDSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edesa Biotech Inc (EDSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edesa Biotech Inc (EDSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edesa Biotech Inc (EDSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nijhawan lifts Edesa Biotech (EDSA) beneficial ownership stake to 19.99% - Stock Titan
Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase - Stock Titan
Edesa Biotech Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Commercial R&D Costs PersistMargin Compression Risk - newsline.com
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
EDSA Q1 2026 Earnings: Misses EPS Estimates Amid Pre-Revenue Stage, Stock Rises 2.65%Mid-Term Outlook - newsline.com
Edesa Biotech Inc. (EDSA) Posts Strong 8.45% Gain, Testing Key ResistanceValue Factor - newsline.com
Edesa Biotech secures $3.5 million private placement financing By Investing.com - Investing.com Australia
Edesa Biotech announces $3.5M private placement - TipRanks
Edesa Biotech Announces Insider-Led PIPE Financing Agreement - TipRanks
Edesa Biotech secures $3.5 million private placement financing - Investing.com
Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares - TradingView
Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO - Stock Titan
CEO backs $3.5M raise to advance Edesa vitiligo work - Stock Titan
Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding - marketscreener.com
Edesa Biotech Company Profile & Introduction - Moomoo
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa reports exploratory data on AKI treatment candidate - Investing.com UK
Edesa reports exploratory data on AKI treatment candidate By Investing.com - Investing.com South Africa
Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients - marketscreener.com
Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA) - Stock Titan
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - GlobeNewswire
Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight - GlobeNewswire Inc.
Edesa Biotech (NASDAQ: EDSA) CEO receives 1,671 restricted share units - Stock Titan
Edesa Biotech Shareholders Approve Directors and Compensation Plans - The Globe and Mail
Edesa Biotech (EDSA) director receives 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director granted 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share RSU award vesting over 12 months - Stock Titan
Edesa Biotech (EDSA) CFO receives 64,609 restricted share units under 2019 plan - Stock Titan
Edesa Biotech (EDSA) president awarded 64,609 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share equity grant, holds 30,000 - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
Edesa Biotech (EDSA) director Da David Liu receives 19,000-share equity grant - Stock Titan
Edesa Biotech (NASDAQ: EDSA) boosts equity plan and reelects full board - Stock Titan
EDSA - Finviz
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026Slideshow - Seeking Alpha
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - Zacks Small Cap Research
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider Than Expected Loss as Clinical Pipeline ProgressesTangible Book Value - Newser
에데사 바이오테크 (EDSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):